Saturday, 10 October 2026European Markets

CONTEXTVISION And EUROFINS SCIENT. Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - contextvision (contx.ol) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
contextvision (contx.ol) kr5.76 3.46% 61.1%
eurofins scient. (erf.pa) €59.08 1.9% 6.16%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. contextvision (contx.ol)

3.46% forward dividend yield and 61.1% return on equity

contextvision ab (publ), a medical technology software company, provides image analysis and imaging for medical systems in asia, europe, and america. the company offers image enhancement software for 2d/3d/4d ultrasound, radiography, magnetic resonance imaging (mri), and veterinary uses. its products include rivent that offers image enhancement and visualization solutions for ultrasound systems for women's health, general imaging, cardiovascular, and point of care applications; rivent mobile, a 2d image enhancement product for handheld units; and rivent 3d, an image enhancement solution for 3d ultrasound. the company also provides altumira/altumira plus, an artificial intelligence-powered image enhancement product for digital radiography; and orthopedic package for orthopedic imaging. in addition, it offers gopview mri2plus, an image enhancement solution for mri. contextvision ab (publ) was founded in 1983 and is headquartered in stockholm, sweden.

earnings per share

as for profitability, contextvision has a trailing twelve months eps of kr0.43.

pe ratio

contextvision has a trailing twelve months price to earnings ratio of 13.4. meaning, the purchaser of the share is investing kr13.4 for every norwegian krone of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 61.1%.

yearly top and bottom value

contextvision's stock is valued at kr5.76 at 12:30 est, way under its 52-week low of kr7.80.

moving average

contextvision's value is way under its 50-day moving average of kr8.37 and way below its 200-day moving average of kr8.72.

more news about contextvision.

2. eurofins scient. (erf.pa)

1.9% forward dividend yield and 6.16% return on equity

eurofins scientific se, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. the company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. it provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. in addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, gmo, grain, meat, nano material, pesticides, and residual dna testing. further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. additionally, the company provides forensic, genomic, maritime, materials and engineering, reach, and other services. the company was founded in 1987 and is headquartered in luxembourg city, luxembourg.

earnings per share

as for profitability, eurofins scient. has a trailing twelve months eps of €1.57.

pe ratio

eurofins scient. has a trailing twelve months price to earnings ratio of 37.63. meaning, the purchaser of the share is investing €37.63 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.16%.

yearly top and bottom value

eurofins scient.'s stock is valued at €59.08 at 12:30 est, below its 52-week high of €63.74 and way higher than its 52-week low of €44.83.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, eurofins scient.'s stock is considered to be overbought (>=80).

more news about eurofins scient..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,366 source documents archived
Query this data → isubstrate.com